Ruxolitinib for Inclusion Body Myositis
Treatments studied
Part of Bones, joints & muscles, Brain & nervous system clinical trials.
This trial tests the drug ruxolitinib (a JAK inhibitor) for people with inclusion body myositis (IBM), a progressive muscle disease. It aims to see if ruxolitinib can help slow muscle weakness and improve function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 45 years or older
- You have a confirmed diagnosis of inclusion body myositis (IBM) based on specific muscle weakness and biopsy findings
- You can walk for 6 minutes without help from another person (cane or walker is okay)
- You are not taking any immune-modulating drugs (like JAK inhibitors) or certain medications that affect muscle growth
- You do not have serious health issues like severe kidney or liver disease, low blood counts, recent heart problems, or certain cancers
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two investigational drugs (pozelimab and cemdisiran) to see if they can help people with sporadic inclusion body myositis, a muscle disease that causes progressive weakness. If the drugs work, they may slow down the disease and help you stay stronger longer.
This trial studies ruxolitinib to treat illnesses where the body makes too many eosinophils (a type of white blood cell) and symptoms or organ damage happen. It may help shrink disease activity when steroids are not enough, cannot be tolerated, or the illness comes back.
This trial tests a new combination of two drugs, ruxolitinib and ulixertinib, for people with myelofibrosis whose disease is not fully controlled by ruxolitinib alone. The goal is to see if adding ulixertinib can improve spleen enlargement, symptoms, or bone marrow changes.
This Phase 2 study tests ruxolitinib (a targeted medicine) in people with essential thrombocythemia or polycythemia vera who still have troublesome symptoms. It aims to see whether it can reduce symptoms by changing disease activity and blood-related inflammation.
This trial tests a new combination of two drugs, roginolisib and ruxolitinib, for people with myelofibrosis whose spleen has not shrunk enough with ruxolitinib alone. It aims to see if adding roginolisib can improve symptoms and spleen size.
This research study examines how diet relates to muscle disease in people with inclusion body myositis (IBM), a rare muscle-weakening condition. Researchers will compare eating habits and nutritional patterns between people with IBM and healthy volunteers to understand how nutrition affects muscle health.
Hear when a new Inclusion Body Myositis, Sporadic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.